Wide Ranks

DXCM

DexCom, Inc.

78.10

Top Statistics
Market Cap 30 B Forward PE 38.57 Revenue Growth 2.00 %
Current Ratio 2.46 Trailing PE 47.33 Earnings Growth 15.70 %
Profit Margins 17.22 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 36.42 Enterprise / Revenue 7.74 Price To Sales Trailing12 Months 7.72
Profitability
Profit Margins 17.22 % Operating Margins 15.29 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 6.38 Total Debt 2 B
Total Debt To Equity 130.94 Current Ratio 2.46 Book Value Per Share 5.07
All Measures
Short Ratio 186.00 % Message Board Id finmb_114039 Shares Short Prior Month 7 M
Return On Equity 0.3206 City San Diego Uuid 3ae7c86d-714e-392b-b6fd-23c89f3c2654
Previous Close 77.94 First Trade Date Epoch Utc 1 B Book Value 5.07
Beta 1.17 Total Debt 2 B Volume 1 M
Price To Book 15.41 Last Split Date 1 B Fifty Two Week Low 62.34
Total Cash Per Share 6.38 Total Revenue 3 B Shares Short Previous Month Date 1 B
Target Median Price 92.00 Max Age 86400 Recommendation Mean 1.60
Sand P52 Week Change 0.3133 Operating Margins 15.29 % Target Mean Price 95.26
Net Income To Common 680 M Short Percent Of Float 0.0264 Implied Shares Outstanding 390 M
Trailing Peg Ratio 122.12 % Last Fiscal Year End 1 B Average Daily Volume10 Day 4 M
Average Volume10days 4 M Total Cash 2 B Next Fiscal Year End 1 B
Revenue Per Share 10.09 Held Percent Insiders 0.0032 Ebitda Margins 21.25 %
Trailing PE 47.33 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 77.94 Target Low Price 75.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 71.11 Open 78.43 Free Cashflow 353 M
State CA Dividend Yield 0.00 % Return On Assets 0.0606
Time Zone Short Name EST Trailing Eps 1.65 Day Low 77.18
Address1 6340 Sequence Drive Shares Outstanding 390 M Price Hint 2
Target High Price 120.00 Website https://www.dexcom.com 52 Week Change -0.3239
Average Volume 4 M Earnings Quarterly Growth 11.50 % Forward Eps 2.03
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 203.30 %
Last Split Factor 4:1 Regular Market Day High 78.62 Is_sp_500 True
Profit Margins 17.22 % Debt To Equity 130.94 Fifty Two Week High 142.00
Day High 78.62 Shares Short 9 M Regular Market Open 78.43
Industry Key medical-devices Earnings Growth 15.70 % Enterprise To Revenue 7.74
Revenue Growth 2.00 % Shares Percent Shares Out 0.0233 Operating Cashflow 821 M
Currency USD Time Zone Full Name America/New_York Market Cap 30 B
Is_nasdaq_100 True Zip 92121 Quote Type EQUITY
Industry Medical Devices Long Name DexCom, Inc. Regular Market Day Low 77.18
Held Percent Institutions 0.9687 Current Price 78.10 Enterprise To Ebitda 36.42
Financial Currency USD Current Ratio 2.46 Gross Margins 61.68 %
Industry Disp Medical Devices Number Of Analyst Opinions 24 Country United States
Float Shares 387 M Two Hundred Day Average 100.81 Ir Website http://www.dexcom.com/about-dexcom/investor-relations
Enterprise Value 30 B Price To Sales Trailing12 Months 7.72 Forward PE 38.57
Regular Market Volume 1 M Ebitda 840 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes.

The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

It markets its products directly to endocrinologists, physicians, and diabetes educators.

The company was incorporated in 1999 and is headquartered in San Diego, California.